ClinicalTrials.gg
RecruitingNCT07519876PEaRLSUpdated Apr 9, 2026

Pulmonary Embolism and Right-to-Left Shunts

An observational study in Pulmonary Embolism (PE), Right-to-Left Shunt and Stroke, sponsored by Tufts Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-09.

Sponsored by Tufts Medical Center · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
256
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 236 studies in Pulmonary Embolism with a site in United States — 34 open to participants now, 43 under way, 6 of them phase 3. Pulmonary Embolism · United States.

Planned enrollment
37th of 68
256 · median 286
Started
2026
with 12 others
Observational
69 of 236
8 open now
Primary completion
2026-02
later than 6 of 42 live
Registered
232nd of 236
by date

Among the 236 studies in Pulmonary Embolism with a site in United States, this one is the 37th largest by planned enrollment of the 68 observational ones that give a count, is one of 13 that started in 2026, is one of 69 observational ones, reaches primary completion later than 6 of the 42 other live ones, and was the 232nd registered.

Pulmonary Embolism

833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.

Browse Pulmonary Embolism studies →

Open to participants now

34 of the 236 studies in Pulmonary Embolism with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Pulmonary Embolism with a site in United States, or all of them as a file.
02

Study summary

Every fetus has a small hole in their heart, called a foramen ovale when they are developing in the womb. For most people this hole closes shortly after birth, but it doesn't close completely in 1 out of every 4 people. This is called a "patent" foramen ovale, or PFO. In people with a PFO it is possible for a blood clot in a vein to enter the heart, pass through the opening, and then go into an artery - this is referred to as a paradoxical embolism which passes through a "Right-to-Left Shunt," or RLS. If this occurs, the blood clot can cause a stroke. The most common RLS (more than 90%) is a PFO. Much rarer causes include other types of holes in the heart (like an atrial septal defect, or ASD), or a vascular communication in the lungs (like a pulmonary arteriovenous malformation, or AVM).

We are investigating whether people with a PE are at higher risk of stroke if they happen to have an RLS compared to PE patients who don't have an RLS. This study will simply observe and compare the differences in stroke-related outcomes between those 2 groups.

Participation in the study last roughly 90-days and includes the following activities:

  • The study team will review your medical records to collect general information such as your age, sex, race/ethnicity, height, weight, medications, medical history, and other medical information
  • Magnetic Resonance Imaging (MRI) of your brain will be done as soon as possible following your enrollment in the study. For more information on MRI scans, please see the "MRI scan" section below.
  • A Transcranial Doppler (TCD) with bubble study will be performed to determine if an opening is present in your heart or lungs. TCD is performed using ultrasound. A contrast called agitated saline will be injected into your vein for this test.
  • You will be asked to return for a follow-up visit 90 days after your pulmonary embolism. At this visit, the following will occur:

    1. A second MRI of your brain will be performed.
    2. You will complete a questionnaire to evaluate whether you may have had a stroke since being discharged from the hospital
    3. You will meet with a member of the study team who will collect information about your health status.
03

Conditions studied

  • Pulmonary Embolism (PE)
  • Right-to-Left Shunt
  • Stroke
  • Atrial Septal Defects
  • Patent Foramen Ovale (PFO)
  • Pulmonary Arteriovenous Malformation

Keywords

  • Pulmonary Embolism
  • PE
  • Right-to-Left Shunt
  • PFO
  • ASD
  • Stroke
  • Atrial Septal Defects
  • Patent Foramen Ovale
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study participants will be selected from the population of patients admitted to Tufts Medical Center

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18
  2. Acute pulmonary embolism (any grade/size)
  3. Patient or legally authorized representative is able to provide consent to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Patients who, in the opinion of the study investigators, are unable to participate in required study activities
  2. Patients unable to undergo MRI imaging
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
256 participants (estimated)
Patient registry
No

Groups and cohorts

  • Right-to-Left Shunt (RLS)

    The RLS cohort includes: a) Subjects found to have a right-to-left shunt (RLS) using transcranial Doppler (TCD) with bubble study b) Subjects with a known RLS (i.e. previously investigated with TCD or TEE)

  • No Right-to-Left Shunt (No RLS)

    The No RLS cohort includes: a) Subjects with no RLS identified via TCD with bubble study b) Subjects known to not have an RLS (i.e. previously investigated with TCD or TEE)

06

What researchers measure

Primary outcomes

  1. Combined incidence of acute ischemic stroke and silent cerebral infarct

    1. Acute ischemic stroke incidence through 90 days defined as an acute focal neurological deficit presumed to be due to focal cerebral or retinal ischemia and either: a) Persisting \>24 hours b) Persisting \<24 hours but associated with a neuroanatomically relevant cerebral or retinal infarct documented with MRI or CT or direct retinal observation. 2. Silent cerebral infarct through 90 days defined as the presence of at least one new hyperintense lesion of 3 mm or greater in diameter on T2-weighted MRI between the screening MRI and the 90-day MRI in the absence of a relevant clinical event.

    Time frame: 90 Days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zhang M, Tan S, Patel V, Zalta BA, Shmukler A, Levsky JM, Jain VR, Shaban NM, Haramati LB. Patent foramen ovale in patients with pulmonary embolism: A prognostic factor on CT pulmonary angiography? J Cardiovasc Comput Tomogr. 2018 Jul-Aug;12(4):271-274. doi: 10.1016/j.jcct.2017.11.009. Epub 2017 Dec 2. PubMed 29217343 ↗
  • Vindis D, Hutyra M, Sanak D, Kral M, Cechakova E, Littnerova S, Adam T, Precek J, Hudec S, Jecmenova M, Taborsky M. Patent Foramen Ovale and the Risk of Cerebral Infarcts in Acute Pulmonary Embolism-A Prospective Observational Study. J Stroke Cerebrovasc Dis. 2018 Feb;27(2):357-364. doi: 10.1016/j.jstrokecerebrovasdis.2017.09.004. Epub 2017 Oct 12. PubMed 29031497 ↗
  • Tanislav C, Puille M, Pabst W, Reichenberger F, Grebe M, Nedelmann M, Kaps M, Allendorfer J. High frequency of silent pulmonary embolism in patients with cryptogenic stroke and patent foramen ovale. Stroke. 2011 Mar;42(3):822-4. doi: 10.1161/STROKEAHA.110.601575. Epub 2011 Jan 21. PubMed 21257827 ↗
  • Lucas TO, Schaustz EB, Dos Reis IJR, Lopes CG, Mendoca VS, Salluh JIF, Zukowski CN, Serafim RB. Risk of ischemic stroke in patients with pulmonary embolism and patent foramen ovale: A systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2025 Jan;34(1):108157. doi: 10.1016/j.jstrokecerebrovasdis.2024.108157. Epub 2024 Nov 30. PubMed 39622459 ↗
  • Lethen H, Flachskampf FA, Schneider R, Sliwka U, Kohn G, Noth J, Hanrath P. Frequency of deep vein thrombosis in patients with patent foramen ovale and ischemic stroke or transient ischemic attack. Am J Cardiol. 1997 Oct 15;80(8):1066-9. doi: 10.1016/s0002-9149(97)00604-8. PubMed 9352979 ↗
  • Le Moigne E, Timsit S, Ben Salem D, Didier R, Jobic Y, Paleiron N, Le Mao R, Joseph T, Hoffmann C, Dion A, Rousset J, Le Gal G, Lacut K, Leroyer C, Mottier D, Couturaud F. Patent Foramen Ovale and Ischemic Stroke in Patients With Pulmonary Embolism: A Prospective Cohort Study. Ann Intern Med. 2019 Jun 4;170(11):756-763. doi: 10.7326/M18-3485. Epub 2019 May 7. PubMed 31060047 ↗
  • Lapergue B, Decroix JP, Evrard S, Wang A, Bendetowicz D, Offroy MA, Graveleau P, Russel S, Ramdane N, Mellot F, Scherrer A, Bourdain F. Diagnostic Yield of Venous Thrombosis and Pulmonary Embolism by Combined CT Venography and Pulmonary Angiography in Patients with Cryptogenic Stroke and Patent Foramen Ovale. Eur Neurol. 2015;74(1-2):69-72. doi: 10.1159/000437261. Epub 2015 Jul 25. PubMed 26228469 ↗
  • Konstantinides S, Geibel A, Kasper W, Olschewski M, Blumel L, Just H. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation. 1998 May 19;97(19):1946-51. doi: 10.1161/01.cir.97.19.1946. PubMed 9609088 ↗
  • Kasper W, Geibel A, Tiede N, Just H. Patent foramen ovale in patients with haemodynamically significant pulmonary embolism. Lancet. 1992 Sep 5;340(8819):561-4. doi: 10.1016/0140-6736(92)92102-l. PubMed 1355152 ↗
  • Goliszek S, Wisniewska M, Kurnicka K, Lichodziejewska B, Ciurzynski M, Kostrubiec M, Golebiowski M, Babiuch M, Paczynska M, Koc M, Palczewski P, Wyzgal A, Pruszczyk P. Patent foramen ovale increases the risk of acute ischemic stroke in patients with acute pulmonary embolism leading to right ventricular dysfunction. Thromb Res. 2014 Nov;134(5):1052-6. doi: 10.1016/j.thromres.2014.09.013. Epub 2014 Sep 21. PubMed 25282541 ↗
  • Doyen D, Castellani M, Moceri P, Chiche O, Lazdunski R, Bertora D, Cerboni P, Chaussade C, Ferrari E. Patent foramen ovale and stroke in intermediate-risk pulmonary embolism. Chest. 2014 Oct;146(4):967-973. doi: 10.1378/chest.14-0100. PubMed 24874409 ↗
  • Clergeau MR, Hamon M, Morello R, Saloux E, Viader F, Hamon M. Silent cerebral infarcts in patients with pulmonary embolism and a patent foramen ovale: a prospective diffusion-weighted MRI study. Stroke. 2009 Dec;40(12):3758-62. doi: 10.1161/STROKEAHA.109.559898. Epub 2009 Sep 24. PubMed 19797184 ↗
  • Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010 Apr;38(4 Suppl):S495-501. doi: 10.1016/j.amepre.2009.12.017. PubMed 20331949 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Feb 2026, 0 months.

Of 135 non-industry observational studies under Pulmonary Embolism, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 119. This study's 0 months is below that.

Counting every sponsor, half of 160 studies reached it within 47 months; a quarter within 21 and three quarters within 105.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
Apr 9, 2026
StartActual
Jan 30, 2026
Primary completionActual
Feb 18, 2026
CompletionEst.
Jan 2028
Last update
Apr 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07519876
Collaborators
Occlutech International AB
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
Jan 30, 2026
Primary completion
Feb 18, 2026
Completion
Jan 2028 (estimated)
Last update
Apr 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion